HML Henderson Mrly.

 

TIDMHML 
 
RNS Number : 1602B 
Henderson Morley PLC 
21 October 2009 
 
21 October 2009 
HENDERSON MORLEY PLC 
("Henderson Morley" or the "Company") 
(AIM: HML) 
AGM STATEMENT 
AGM statement 
At the Company's Annual General Meeting held at 1100 hours today all resolutions 
were duly passed. 
Chairman, Andrew Knight, made the following statement to shareholders during the 
meeting: 
"On behalf of the Board of Henderson Morley, I am pleased to report on the 
current status of the Company's various research projects. 
 Divestment of ICVT 
"As announced on 9 October 2009, the Company has received a letter of intent 
from a potential purchaser of the ICVT human platform (excluding ophthalmic and 
orphan indications).The proposed sale of this IPR is still subject to further 
negotiation even though discussions are now at a stage where it is anticipated 
that a deal acceptable to each party will be completed by the end of 2009. 
"The Company is also in discussion with a further potential purchaser which has 
also shown interest in acquiring certain indications of the technology. 
"The Board expects to provide further updates on each of these negotiations once 
any definitive agreements have been signed. 
 Animal Health 
"The data from the Koi Herpes virus challenge studies in Koi carp has been fully 
analysed by the Company's scientists and has been sent to Schering Plough Animal 
Health for their opinion. 
 
 "The Company is in talks with a European animal health pharmaceutical 
company with a view to licensing the animal health application of ICVT for the 
treatment of feline herpes ("FHV"). A study into FHV is currently ongoing under 
the supervision of Triveritas (an animal health Contract Research Organisation). 
 "The Company is also in discussions with animal health companies to co-develop 
the animal health applications of PREPS and L-Particles in the treatment of 
canine cancer. 
 PREPS and L-Particles 
"The Company has now sent the PREPS and L-Particles, which have been engineered 
to express Epstein Barr Poly-epitope, to the Australian Centre for Vaccine 
Development (ACVD). The ACVD has confirmed that the initial antigenicity studies 
are now underway and the results from these studies are expected within the next 
few weeks. 
"The Company has also sent validated L-Particles to the Influenza Centre of 
Excellence at the University of Georgia where scientists will examine their role 
as biological adjuvants in naked DNA vaccination. The studies are designed to 
determine if their co-administration potentiates the role of naked DNA influenza 
vaccines in influenza models. The results of these studies are expected before 
the end of the year. 
"We stated at the time of the fundraising in early June that the Company 
anticipated, in the following six months, receiving income in the form of 
disposal proceeds from the sale of ICVT for human applications and licensing 
income from other developed products in the pipeline.  As is not uncommon for 
the industry in which the Company operates, the estimation of the timing of 
income from disposals and licensing is not an exact science. The Board is 
disappointed that near term revenue bearing agreements are taking longer than 
anticipated, however the Board is continuing to review its options and remains 
of the belief that each of these agreements will be concluded. 
"Your Board remains focused on our stated strategy to divest ICVT; spin out the 
animal health, orphan and ophthalmic parts of the company, and to focus on 
becoming a pure play vaccine company by 2011." 
 
-END- 
 
Enquires 
 
HENDERSON MORLEY PLC                               0121 442 4600 
Andrew 
Knight, Chairman 
BISHOPSGATECOMMUNICATIONS LTD            0207 562 3350 
Maxine Barnes 
Gemma 
O'Hara 
BREWIN DOLPHIN INVESTMENT BANKING        0113 241 0126 
Neil Baldwin 
RIVINGTON STREET CORPORATE FINANCE        0207 562 3380 
Monisha Varadan 
 
Further information on Henderson Morley plc can be accessed through the 
Company's website at www.henderson-morley.com 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 AGMFESFFFSUSEDS 
 

Grafico Azioni Henderson Mrly. (LSE:HML)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Henderson Mrly. (LSE:HML)
Storico
Da Giu 2023 a Giu 2024